Astellas Pharma Gmbh

Medivation Prostate Therapeutics, Inc.

Ambit Biosciences Corporation

Shinsuke Oba

Toshiro Sakai

Koji Nishimura

Douglas Alan Lorenz

Yuuki Takaishi

Sanjay Konagurthu

Hiroyasu Toyota

Randy J Wald

Atsushi Kanbayashi

Jason A Everett

Ryousuke Irie

Akira Takagi

Takumi Hara

Emiko Murayama

Hajime Aoki

Takatsune Yoshida

Ryo Kojima

Sachie Namiki

Yoshiaki Umemoto

Sheila Matz

Satomi Ikeuchi

Kei Motonaga

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Formulations of enzalutamide

Provided is a pharmaceutical composition for oral administration in which the solubility and/or dissolution properties of enzalutamide are improved and supersaturation is maintained. Also provided is a pharmaceutical composition for oral administration in which the oral absorbability of enzalutamide is improved. The pharmaceutical composition for oral administration comprises enzalutamide and polyvinyl alcohol.

Pharmaceutical composition for oral administration comprising enzalutamide

Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N&#x2032;-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-&#x3b2;-cyclodextrin in a ratio ranging from 1:8 to 1:20.

Tablet containing composite with cyclodextrin

Growing community of inventors

Tokyo, Japan

Shinsuke Oba